Figure 2

Plasma concentration versus time profiles for enzalutamide ASDs prepared with novel cellulose derivatives, SEDDS prepared with Labrasol, and a crystalline slurry. Formulations contained 4.5 (SEDDS formulation), 10 (CPHPC-106) or 50% CPHPC-106 and CA Sub) by weight of drug.